Topigen names new CFO

Mr Boisjoli most recently served as CFO and co-founder of Xanthus Pharmaceuticals, a Boston-based biotechnology company, where he was responsible for all financial business and operations and was instrumental in the acquisition of Xanthus by Antisoma in June 2008.

Mr Boisjoli is a chartered accountant and chartered business valuator and holds a bachelor of commerce degree and a graduate diploma in accountancy from Concordia University.

In addition, the company announced strategic additions to its scientific advisory boards. Marianne Mann, former deputy director of the FDA division of pulmonary and allergy drug products, has been appointed to Topigen’s clinical advisory board. Topigen’s research advisory board has also been expanded to include Elizabeth Vadas, previously executive director of pharmaceutical R&D at Merck.

Mark Parry-Billings, CEO of Topigen, said: “Robert brings to Topigen extensive and diverse financial and operational management experience. He will play a pivotal role in the company as we advance our pipeline of innovative therapeutics for respiratory diseases.”